Table S1: Baseline donor-specific antibody levels for eculizumab and control patients as determined by various assays including: The B flow cytometric crossmatch channel shift (BFXM), the T-cell antihuman globulin cytotoxicity crossmatch (TAHG, N = negative, P = positive) and the highest measured antidonor HLA specificity as determined by the solid-phase LABscreen assay (MFI). Patients who developed AMR after transplant are listed separately from those who did not develop AMR (no AMR)

Table S2: Creatinine and DSA levels after transplantation, creatinine and DSA levels of eculizumab-treated patients, creatinine and BFXM data of the control group

Table S3: Banff scores of biopsies of eculizumab-treated patients and Banff scores of biopsies of the control group

AJT_3757_sm_TableS1.doc138KSupporting info item
AJT_3757_sm_TableS2.doc167KSupporting info item
AJT_3757_sm_TableS3.doc247KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.